Memantin Startpackung Abdi

Memantine Hydrochloride, the active ingredient in Memantin Startpackung Abdi, is a NMDA receptor antagonist presented as an oral formulation for oral use. It treats moderate to severe Alzheimer's disease in adults. GNH USA supplies Memantin Startpackung Abdi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is an NMDA receptor antagonist used in the management of Alzheimer's disease and related cognitive disorders, acting on glutamatergic pathways.

Alzheimer's disease (moderate to severe): Improves cognition, memory, and daily functioning in patients with moderate to severe disease. Behavioral symptoms of Alzheimer's disease: May reduce agitation, aggression, and psychotic features associated with the condition. Vascular dementia with overlapping Alzheimer's pathology: May provide modest benefit in cognition when co‑existent.

Memantine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: transient disorientation. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome. - Seizures: new onset or worsening of pre‑existing seizures. - Cardiac arrhythmias: irregular heart rhythms requiring medical attention.

Memantine should be used with caution in specific clinical situations. - Renal impairment: adjust dose according to renal function. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: use carefully in patients with uncontrolled hypertension or arrhythmias. - Concurrent NMDA antagonists: avoid combined use to reduce risk of additive CNS effects. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Memantine may interact with several medicines; monitoring is recommended.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase toxicity. - Other NMDA antagonists (e.g., ketamine): risk of excessive central nervous system depression. - Strong CYP450 inhibitors (e.g., ketoconazole): may raise memantine plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of memantine. - Anticholinergic agents: may diminish therapeutic benefit of memantine.